Press Releases
Site - Investor Relations
Predictive Oncology Reports That Its Wholly Owned Subsidiary, TumorGenesis, Has Sold Media to Two Top Research Medical Centers
“We believe that this is the future of ovarian cancer research, which creates new possibilities to coming up with new treatments for this chronic and deadly disease. In order for us to find better drugs, we have to be able to grow the right patient cells in the right media. Building the ‘living library’ of cancer cells for drug screening and discovery is the right first step. Then we can focus on how to kill them,” said Dr.
“The concept that we can replicate the ovarian cancer cells outside of the patient’s body and in a laboratory well plate or culture flask is remarkable," said
The 3D cancer cell culture media market is expected to grow at CAGR of approximately 11.3%, to
About
Forward-Looking Statements
Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements because of a variety of factors including, among other things, the possibility that market acceptance of our products would be being slower than expected, the possibility of facing challenges in management of growth or other factors discussed under the heading “Risk Factors” in our filings with the
Investor Relations Contact:
(404) 995-6671
kpinder@landoncapital.net
Source: Predictive Oncology Inc.